Insight Molecular Diagnostics Inc. (IMDX) — Cash Flow-to-Debt Ratio
Insight Molecular Diagnostics Inc. (IMDX) has a Cash Flow-to-Debt Ratio of -0.15x as of March 2026, meaning its operating cash flow of $-7.64 Million could theoretically repay 0% of its total liabilities ($51.12 Million) in one year. See IMDX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Insight Molecular Diagnostics Inc. Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Insight Molecular Diagnostics Inc. across 13 annual periods. For the full cash flow conversion analysis, see Insight Molecular Diagnostics Inc. cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Insight Molecular Diagnostics Inc. (2013–2025)
Year-by-year debt coverage analysis for Insight Molecular Diagnostics Inc.. Check earnings quality score of Insight Molecular Diagnostics Inc. to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.39x | $-22.18 Million | $57.22 Million | ▲ +11.4% |
| 2024 | -0.44x | $-20.71 Million | $47.35 Million | ▼ -2.1% |
| 2023 | -0.43x | $-23.32 Million | $54.42 Million | ▲ +43.1% |
| 2022 | -0.75x | $-45.57 Million | $60.50 Million | ▼ -97.7% |
| 2021 | -0.38x | $-35.94 Million | $94.35 Million | ▲ +67.8% |
| 2020 | -1.18x | $-25.98 Million | $21.94 Million | ▲ +45.8% |
| 2019 | -2.19x | $-19.71 Million | $9.02 Million | ▼ -14.3% |
| 2018 | -1.91x | $-11.65 Million | $6.09 Million | ▲ +17.0% |
| 2017 | -2.30x | $-13.38 Million | $5.81 Million | ▼ -40.4% |
| 2016 | -1.64x | $-7.52 Million | $4.58 Million | ▲ +10.2% |
| 2015 | -1.83x | $-4.23 Million | $2.31 Million | ▼ -1066.6% |
| 2014 | -0.16x | $-1.16 Million | $7.43 Million | ▼ -3.1% |
| 2013 | -0.15x | $-710.00K | $4.67 Million | — |